Research Paper Volume 16, Issue 5 pp 4378—4395
The prognosis, chemotherapy and immunotherapy efficacy of the SUMOylation pathway signature and the role of UBA2 in lung adenocarcinoma
Figure 6. The prognostic value of SUMOPS for ICI treatment. (A–C) Scores of (A) TIDE, (B) T cell dysfunction and (C) T cell exclusion in different SUMOPS subtypes. (D) Box plots illustrating the relationships between SUMOPS subtypes and the expression of immune checkpoints. *p < 0.05; **p < 0.01, ***p < 0.001.